BioWorld

Jan. 14, 2003

FDA Panel Appears To Support Genzyme's BLA For Fabry Drug

BETHESDA, Md. - An FDA panel on Monday said Genzyme General's surrogate endpoint from its Phase III trial of Fabrazyme in Fabry disease patients is likely to predict a clinically meaningful effect. (BioWorld Today) Read More

Elixir, Centagenetix Plan To Merge Complementary Aging Programs

Identifying, Isolating Adult Stem Cells Widens Path To Variety Of Futuristic Anticancer Treatments

Aventis Picks Five Eos Targets; Vaccine Deal Ends With 'Bang'

Amylin Files For $141.7M Public Offering From Shelf

BioFocus Enters Amgen Deal, Offers Warning On Financials

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...

Insilico Medicine synthesizes new Nav1.8 blockers

BioWorld Science

Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.